Ozanezumab Dose Selection for Amyotrophic Lateral Sclerosis by Pharmacokinetic-Pharmacodynamic Modelling of Immunohistochemistry Data from Patient Muscle Biopsies

Open Access

Peer-reviewed

Research Article

Alienor Berges,

Affiliation Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, London, United Kingdom
⨯
Jonathan Bullman,

Affiliation Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, London, United Kingdom
⨯
Stewart Bates,

Affiliation Biopharm Translational Medicine, GlaxoSmithKline, Stevenage, United Kingdom
⨯
David Krull,

Affiliation Safety Assessment, GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America
⨯
Nicola Williams,

Affiliation Clinical Statistics, GlaxoSmithKline, Stevenage, United Kingdom
⨯
Chao Chen

* E-mail: nchao.c.chen@gsk.com

Affiliation Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, London, United Kingdom
⨯

Reader Comments (0)

Biopsy
Is the Subject Area "Biopsy" applicable to this article?

Thanks for your feedback.
Amyotrophic lateral sclerosis
Is the Subject Area "Amyotrophic lateral sclerosis" applicable to this article?

Thanks for your feedback.
Immunohistochemistry techniques
Is the Subject Area "Immunohistochemistry techniques" applicable to this article?

Thanks for your feedback.
Dose prediction methods
Is the Subject Area "Dose prediction methods" applicable to this article?

Thanks for your feedback.
Cell membranes
Is the Subject Area "Cell membranes" applicable to this article?

Thanks for your feedback.
Pharmacology
Is the Subject Area "Pharmacology" applicable to this article?

Thanks for your feedback.
Simulation and modeling
Is the Subject Area "Simulation and modeling" applicable to this article?

Thanks for your feedback.
Skeletal muscles
Is the Subject Area "Skeletal muscles" applicable to this article?

Thanks for your feedback.